Physician profile
Jose Bonelli
NPI 1396829628
$40,084.07
in general payments reported to CMS, 2019-2025
69 companies · $5,167 in 2025
The $5,167 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,273 · 2020: $3,177 · 2021: $4,116 · 2022: $4,316 · 2023: $4,486 · 2024: $14K · 2025: $5,167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Consulting Fee: $5,250 · Travel and Lodging: $2,681.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,271.05 |
| Consulting Fee | $5,250.00 |
| Travel and Lodging | $2,680.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $9,946.32 | 2019-2025 | Kisunla, Mounjaro, Jardiance |
| Novo Nordisk INC | $5,616.59 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $3,984.97 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $2,540.40 | 2019-2025 | Vraylar, Ubrelvy, Linzess |
| Corcept Therapeutics | $1,347.92 | 2019-2023 | Korlym |
| Kowa Pharmaceuticals America, INC. | $1,319.07 | 2019-2025 | Livalo, Seglentis, Zoryve |
| Amgen INC. | $1,245.79 | 2019-2025 | Evenity, Repatha, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,093.86 | 2019-2025 | Jardiance |
| Gilead Sciences, INC. | $1,069.94 | 2020-2025 | Biktarvy, Descovy |
| Otsuka America Pharmaceutical, INC. | $1,050.17 | 2023-2025 | Rexulti |
| Pfizer INC. | $864.28 | 2019-2025 | |
| Scilex Pharmaceuticals INC. | $825.19 | 2019-2025 | Ztlido |
| Bayer Healthcare Pharmaceuticals INC. | $687.43 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $649.61 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $640.39 | 2022-2025 | Caplyta |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $609.15 | 2019-2020 | |
| Amarin Pharma, INC. | $590.45 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $586.14 | 2020-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Abbott Laboratories | $582.43 | 2019-2025 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $461.26 | 2019-2024 | Eliquis, Camzyos |
| Arcutis Biotherapeutics, INC. | $406.44 | 2023 | |
| Glaxosmithkline, LLC. | $288.92 | 2022-2025 | Arexvy, Shingrix |
| Arbor Pharmaceuticals, INC. | $267.31 | 2019-2022 | |
| Antares Pharma, INC. | $266.64 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Takeda Pharmaceuticals U.S.A., INC. | $257.89 | 2019-2021 | |
| Grifols USA, LLC | $221.23 | 2019 | |
| Exact Sciences Corporation | $197.23 | 2023-2025 | Cologuard Collection Kit |
| Lundbeck LLC | $163.19 | 2024-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $160.93 | 2020-2025 | |
| Axsome Therapeutics, INC. | $143.57 | 2025 | Auvelity |
| Valeritas, INC. | $134.83 | 2019 | |
| Sanofi-Aventis U.S. LLC | $131.19 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $129.02 | 2024 | Gvoke Hypopen, Recorlev |
| Viiv Healthcare Company | $128.24 | 2022-2023 | Apretude |
| Noven Pharmaceuticals, INC. | $124.99 | 2024 | Xelstrym |
| Radius Health, INC. | $123.02 | 2025 | Tymlos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $107.32 | 2024-2025 | Xifaxan |
| Helsinn Therapeutics (U.S.), INC. | $77.52 | 2019 | |
| Aclaris Therapeutics, INC. | $75.59 | 2019 | |
| Endo USA, INC. | $74.98 | 2024-2025 | Xiaflex, Aveed, Edex |
| Azurity Pharmaceuticals, INC. | $69.78 | 2023-2024 | Edarbi, Horizant, Edarbi |
| Dexcom, INC. | $66.05 | 2021-2025 | Dexcom G6 Transmitter |
| Alfasigma USA, INC. | $55.74 | 2021 | |
| Janssen Biotech, INC. | $48.84 | 2019 | |
| Phadia US INC. | $48.81 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $46.28 | 2023 | Edex, Xiaflex, Aveed |
| Sumitomo Pharma America, INC. | $44.07 | 2025 | Gemtesa |
| Lucira Health, INC. | $42.78 | 2022 | |
| Idorsia Pharmaceuticals US INC | $38.40 | 2023 | Quviviq |
| Ani Pharmaceuticals, INC. | $38.12 | 2024 | Purified Cortrophin Gel |
| Actelion Pharmaceuticals US, INC. | $31.30 | 2023 | Opsumit |
| Dynavax Technologies Corporation | $31.03 | 2022 | |
| Hologic Sales and Service, LLC | $25.49 | 2025 | Aptima |
| Sanofi Pasteur INC. | $25.48 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $23.48 | 2020 | |
| Noven Therapeutics, LLC | $23.32 | 2024 | Xelstrym |
| Halozyme INC | $22.55 | 2023 | |
| Ibsa Pharma INC. | $22.13 | 2023 | Tirosint, Licart |
| Biohaven Pharmaceutical Holding Company Ltd. | $21.44 | 2022 | |
| Seqirus USA INC | $20.38 | 2024 | Fluad, Flucelvax |
| Medtronic, INC. | $19.71 | 2024 | Intellis Adaptivestim |
| Recordati_rare_diseases_inc. | $19.32 | 2024 | Isturisa |
| Horizon Therapeutics Plc | $17.15 | 2020 | |
| Vifor Pharma, INC. | $17.01 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $16.67 | 2021 | |
| Smith+Nephew, INC. | $15.69 | 2019 | |
| Tactile Systems Technology INC | $14.34 | 2025 | Nimbl, Flexitouch Plus |
| Astellas Pharma US INC | $14.12 | 2021 | |
| Zyla Life Sciences, INC. | $13.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Bonelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.